C oronary atherosclerosis is a complex and dynamic multifactorial disease that depends on the exchange of biochemical messages by resident cells (endothelial and smooth muscle cells) and infiltrating leukocytes that regulate functions critical to lesion initiation and progression and to the clinical manifestations of coronary artery disease. 1 The clinical manifestations include stable or unstable angina, acute myocardial infarction, and sudden cardiac death. An episodic increase in vasomotor tone of epicardial coronary arteries is an important pathological component of a number of these ischemic cardiac syndromes; however, its causes remain unclear. [2] [3] [4] Infiltrating leukocytes provide a source of a number of vasoactive mediators with the potential to produce these effects.
Leukotrienes are a class of biologically active lipids, synthesized and released from leukocytes, that have a variety of proinflammatory effects. 5, 6 The synthetic pathway for leukotrienes is initiated by the release of arachidonic acid from the cell membrane by phospholipase A 2 , followed by its conversion to leukotriene A 4 (LTA 4 ) by the enzyme 5-LO and its activating protein, FLAP. 7, 8 LTA 4 is either converted to LTB 4 by the enzyme LTA 4 hydrolase 9, 10 or is conjugated with glutathione to form the cysteinyl leukotriene LTC 4 . 11 The cysteinyl leukotrienes include LTC 4 and its metabolites, LTD 4 12 and LTE 4 . 13 There is a growing body of evidence suggesting a putative role of leukotrienes in coronary heart disease. 14 In particular, the cysteinyl leukotrienes are potent vasoconstrictors of coronary arteries of several species [15] [16] [17] and have been shown to be associated with myocardial ischemic events, such as in experimentally induced myocardial infarction 18 and in "cardiac anaphylaxis." 19 In addition, inhibitors of 5-LO 20 and cysteinyl leukotriene receptor antagonists 21 are effective in reducing infarct size and reperfusion-induced arrhythmias in animal models of experimental ischemia. These studies, together with recent clinical evidence of an increased production of cysteinyl leukotrienes in patients with coronary artery disease, 22, 23 implicate involvement of leukotrienes in coronary heart disease. Therefore, to assess their role in coronary artery disease, we compared the contractile responses of LTC 4 and LTD 4 and their binding activity in both atherosclerotic and nonatherosclerotic human coronary arteries. We also studied expression of the enzymes that control their formation to understand how the 5-LO pathway is activated in human coronary arteries. 
Methods

Materials
Patient Details
Human epicardial coronary arteries were removed from explanted hearts of 44 patients at the time of cardiac transplantation. Informed consent was obtained from each patient, and the study was approved by the Harefield Hospital Ethical Committee. Atherosclerotic arteries were obtained from 22 patients with previously diagnosed IHD who had obstructive coronary lesions by angiography (mean age, 57 years; range, 49 to 63). Nonatherosclerotic arteries were obtained from 22 patients undergoing transplantation for reasons other than IHD (mean age, 30 years; range, 4 to 53). The latter group comprised 18 patients with DCM, 3 with congenital heart defects, and 1 with cystic fibrosis. These arteries were free from atheroma on microscopic and histological examination, although they occasionally showed evidence of mild intimal proliferation.
Organ Bath Experiments
LTC 4 and LTD 4 Responses
Left anterior descending and right coronary arteries from both proximal and distal regions of the vessels were dissected free from the surrounding myocardium, cut into ring segments, and mounted for isometric tension recording as described previously. 24 In some experiments, ring segments of atherosclerotic arteries were incubated with acivicin (50 mol/L), an irreversible ␥-glutamyl transpeptidase inhibitor that prevents the metabolism of LTC 4 to LTD 4 . 25, 26 In another group of atherosclerotic artery segments, LTD 4 concentration-response curves were performed in the presence of L-cysteine (3 mmol/L) to block the metabolism of LTD 4 to LTE 4 .
26,27
Endothelial Modulation of LTD 4 Responses
Because LTD 4 can stimulate release of endothelium-derived nitric oxide, 28 a separate series of experiments was conducted to investigate whether LTD 4 responses could be affected by the endothelium. Vessels were incubated with indomethacin (10 mol/L) to block the synthesis of relaxing prostaglandins before the addition of LTD 4 . In another group of experiments, vessels were preconstricted with the thromboxane mimetic U46619 (1 to 3 nmol/L) or prostaglandin F 2␣ (1 mmol/L), whereas in other vessels the endothelium was removed before the tissues were challenged with LTD 4 . Removal of the endothelium was confirmed by the absence of relaxation to the endothelium-dependent relaxation factor substance P.
In Vitro Receptor Autoradiography
Epicardial coronary arteries were obtained from six patients undergoing heart transplantation (three DCM and three IHD) and snapfrozen in liquid nitrogen. Tritiated leukotriene binding sites in atherosclerotic and nonatherosclerotic coronary arteries were localized with the use of in vitro receptor autoradiography. The optimum incubation time (association experiments) and wash times (dissociation experiments) had been determined previously. 26 4 binding was performed by wiping off tissue sections from the microscope slides with Nucwipes (National Diagnostic), which were then placed in Ultragold scintillant (4.5 mL) and counted for tritium as described previously.
26
Immunocytochemistry of 5-LO, FLAP, and LTA 4 Hydrolase
The left anterior descending arteries from eight hearts were obtained from patients undergoing transplantation (five DCM and three IHD). Frozen sections 6-m thick were cut, and rabbit anti-5LO (diluted 1:400), rabbit anti-FLAP (diluted 1:300), rabbit anti-LTA 4 hydrolase (diluted 1:1200), or mouse monoclonal anti-CD68 (diluted 1:1000) was applied to the sections, which were incubated for 1 hour. Tissues were then stained according to the manufacturer's instructions.
Data Analysis
Contractions were measured as a percentage of the maximal isometric contraction to 90 mmol/L KCl. The E max value refers to the maximum response at the highest dose of leukotriene, and the EC 50 value for each concentration-effect curve was obtained by linear regression analysis of data points in grams or percentage of KCl response versus log concentration above and below the EC 50 level. These values were transformed into pD 2 values (Ϫlog EC 50 ). All results are shown as meanϮSEM, and in all experiments, n equals the number of patients from whom the vessels were obtained. Differences between leukotrienes were compared by unpaired Student's t test. Comparisons between control and experimental groups were made by ANOVA followed by a Bonferroni correction. A value of PϽ.05 was considered a statistical difference.
Results
Effect of LTC 4 and LTD 4 on Vasomotor Tone
Nonatherosclerotic coronary artery ring segments were unresponsive to LTC 4 and LTD 4 from each of the three nonatherosclerotic groups (Figure 1; nϭ8) . In contrast, LTC 4 and LTD 4 induced concentration-dependent contractions in atherosclerotic coronary arteries (Figure 1; nϭ11) . The potency (EC 50 ) and maximum response (E max ) to LTC 4 were 11.1 nmol/L (95% CI, 9.4 to 13.0) and 62Ϯ8.4%, respectively, and EC 50 and E max for LTD 4 were 7.0 nmol/L (95% CI, 1.3 to 36) and 32Ϯ6.5%, respectively (PϽ.05, E max for LTC 4 versus LTD 4 ). The degree of contraction of the atherosclerotic vessels induced by LTC 4 and LTD 4 after pretreatment with indomethacin was unchanged, indicating that constricting prostaglandins such as thromboxane A 2 were not involved (data not shown). Furthermore, responses to each leukotriene were prolonged (usually 20 to 30 minutes for each concentration response to plateau) and difficult to wash out.
Selected Abbreviations and Acronyms
DCM ϭ dilated cardiomyopathy FLAP ϭ 5-lipoxygenase activating protein IHD ϭ ischemic heart disease 5-LO ϭ 5-lipoxygenase LT ϭ leukotriene Vessel segments treated with vehicle (MeOH:H 2 O:AcOH) to control for the solvent that the leukotrienes were dissolved in had no effect on basal vessel tone (0 mN above baseline, nϭ6), indicating that the contractions were due to the leukotriene and not to the solvent. The unresponsiveness of the nonatherosclerotic arteries was specific to the leukotrienes and not due to damage of the vessels, because both thromboxane A 2 and serotonin produced contractions in the same coronary arteries (data not shown).
Influence of Endothelium-Dependent Relaxing Factors on LTD 4 Responses
In the presence of indomethacin or in vessel segments in which the endothelium had been removed, nonatherosclerotic coronary arteries remained unresponsive to LTD 4 (0 mN, nϭ6). When nonatherosclerotic arteries were preconstricted with the thromboxane analogue U46619 or prostaglandin F 2␣ , LTD 4 (1 pmol/L to 0.1 mol/L) failed to induce relaxations in the arteries (data not shown). The fact that there were no relaxation responses to LTD 4 was not because of damage to the endothelium, because the endothelium-dependent vasodilator substance P (10 nmol/L) induced relaxations in preconstricted coronary artery segments (data not shown). These results confirm our previous findings, which showed that LTC 4 responses in atherosclerotic coronary arteries were not influenced by the endothelium. In both nonatherosclerotic and atherosclerotic arteries, the degree of nonspecific binding (in the presence of excess unlabelled leukotriene) was high (50% to 80%), particularly at 3 nmol/L. To quantitatively assess the degree of specific binding to establish any differences in the amount of binding in the two vessel types (particularly at the low concentrations in which binding was too low to image), we estimated the amount of binding to both vessels by counting tritium levels. 
High-Resolution Autoradiography of Atherosclerotic Coronary Arteries
Because LTC 4 was the only leukotriene that showed significant specific binding in atherosclerotic coronary arteries, we used high-resolution autoradiography to identify the cell types to which LTC 4 was binding. High-resolution images of atherosclerotic vessels showed dense [ 3 H]-LTC 4 binding that was mainly localized to the medial smooth muscle cells, with less binding to adventitia (data not shown). In atherosclerotic coronary arteries, there was also additional binding to regions of intimal proliferation and very dense binding to areas of plaque ( Figure 5 ). There was no evidence of [ 3 H]-LTC 4 binding to the endothelium.
5-LO, FLAP, and LTA 4 Hydrolase Expression in Human Coronary Arteries
Immunocytochemical staining demonstrated macrophages in the adventitia of nonatherosclerotic vessel segments ( Figure   6 ), with greater numbers in the atherosclerotic vessels (data not shown). In addition, some macrophages were also present in the media, whereas areas of intimal proliferation associated with the atherosclerotic coronary arteries were abundant with macrophages ( Figure 7 ). Generally increased numbers were seen in the intima with increasing severity of disease. The more-advanced diseased arteries also had a few macrophages in the media. Cells positive for 5-LO, FLAP, and LTA 4 hydrolase were also seen in the adventitia and in areas of intimal proliferation that corresponded to the distribution of the macrophages (Figure 7 ). In these areas, 5-LO labeled the greatest number of cells, with FLAP present in a smaller percentage and LTA 4 hydrolase generally demonstrating the least number of positive cells. All negative control sections had no staining. Thus, compared with the nonatherosclerotic vessels ( Figure 6 ), atherosclerotic arteries ( Figure 7 ) contained a greater number of infiltrating macrophages and hence a greater amount of enzymatic machinery to produce leukotrienes. An unexpected finding was that the medial smooth muscle cells of both vessel types were also positive with all three leukotriene antibodies to a similar extent ( Figures 6 and 7) . In preliminary experiments, we also found some positive staining for 5-LO, FLAP, and LTA 4 hydrolase in the cultured smooth muscle cells derived from human coronary arteries (data not shown). The degree of positive staining was variable between smooth muscle cell cultures derived from different patients.
Discussion
These results show for the first time that the presence of atherosclerosis in human coronary arteries specifically augments contractions to cysteinyl leukotrienes and provides an enzymatic capacity within the vessel wall in the form of infiltrating macrophages and possibly smooth muscle cells to produce leukotrienes that could contribute to the hyperreactivity of atherosclerotic vessels. Hyperreactivity of human atherosclerotic coronary arteries to LTC 4 and LTD 4 was unaffected by endothelium-derived mediators. Previous reports 29 have shown increased responsiveness of atherosclerotic arteries to serotonin that was unaffected by the endothelium. In those studies, hyperreactivity was reported to involve an increased responsiveness of the receptor or signal transduction system that was not apparent in the receptors present in the nondiseased arteries. Our present findings provide no evidence of cysteinyl leukotriene receptors in nonatherosclerotic epicardial coronary arteries, as suggested by the inability to contract to LTC 4 or LTD 4 and confirmed by the absence of a significant number of specific [ 3 H]-leukotriene binding sites. In contrast, atherosclerotic vessels responded with potent contractions to LTC 4 and with smaller contractions to LTD 4 , and a significant number of specific [
3 H]-LTC 4 binding sites were present in the atherosclerotic vessels. These results confirm and extend our previous findings 24 and suggest a novel mechanism whereby specific leukotriene receptors associated with atherosclerotic vessels may explain the augmented response to these leukotrienes.
There 30 rat, 31 and human lung. 32 However, these data are difficult to interpret owing to a large number of independent LTC 4 specific binding sites reported to be present in the membranes under investigation. The relevance of the LTC 4 binding sites is still unclear, with results from many groups supporting the conclusions of an early report 33 describing glutathione-S-transferase as the LTC 4 34 who showed that angioplasty triggers intracoronary leukotriene production and who suggested that plaque rupture may be the stimulus triggering the appearance of these vasoactive compounds and that they may be derived from the atherosclerotic plaque itself or from the interaction of the released plaque debris with peripheral blood cells. There is now evidence that localized chronic inflammatory processes within the atherosclerotic plaque, rather than the endothelium, are responsible not only for plaque rupture itself but also for the hyperreactivity of these vessels to vasoconstrictor stimuli. 35 The enhanced reactivity of the epicardial coronary arteries from IHD patients observed here, together with the evidence of leukotriene binding to plaque, appears to suggest that a local or systemic release of leukotrienes in response to tissue injury might contribute to spasm of a coronary vessel segment and/or precipitate a plaque rupture.
Human coronary arteries not only have the ability to contract to leukotrienes, they also have the capacity to produce leukotrienes. Previous work 36 has shown that human and canine coronary arteries can produce leukotrienes when stimulated with calcium ionophore or treated with arachidonic acid. In the present study, we identified staining of 5-LO, FLAP, and LTA 4 hydrolase that appeared to be associated with macrophages. The amount of staining for each leukotriene protein was increased in the atherosclerotic vessels and appeared to correlate with the presence of increased numbers of macrophages.
Monocyte/macrophage recruitment to the vascular intima followed by foam cell transformation is a crucial early step in the development of atherosclerosis, and there is increased evidence that leukotrienes can play a role in this process. For example, 5-LO inhibitors can prevent the uptake of cholesterol esters into monocytes and macrophages in vitro. 37 In addition, oxidized LDL can increase 5-LO activity in a mononuclear cell line, 38 suggesting that in vivo oxidized LDL may play an important role in the upregulation of the 5-LO pathway. This is important because LDL is known to stimulate leukotriene production in monocytes. 39 Furthermore, we have recent data to suggest that there is an overproduction of LTB 4 in patients with hypercholesterolemia (unpublished data from our laboratory, 1998). Leukotriene B 4 is chemotactic for monocytes 40 and can cause increased adhesion of leukocytes to the vascular endothelium. 41 Taken together, the above evidence suggests that activation of the macrophage 5-LO pathway may play an important role in the inflammatory response associated with migration and transformation into foam cells of macrophages within the vessel intima. The importance of the 5-LO pathway in inflammation has recently been highlighted in 5-LO and FLAP knockout mice 42 in studies that showed a blunted inflammatory response to topical arachidonic acid and platelet activating factor-induced shock compared with controls.
In conclusion, we present evidence of a novel mechanism in which atherosclerosis is associated with the appearance of a leukotriene receptor(s) capable of inducing hyperreactivity of human epicardial coronary arteries in response to LTC 4 and LTD 4 . Because heart tissue has the capacity to both produce and respond to leukotrienes and because patients with coronary artery disease have raised levels of leukotrienes, the present findings suggest that endogenous leukotrienes may play an important role in the pathogenesis and clinical manifestations of atherosclerosis.
